CAPITAL4 NEWS

 

  • NIFTY4,860.5  
  • -45.6 -0.9%
  • SENSEX16,026.4  
  • -156.9 -1.0%

Strides Arcolab receives USFDA approval

Source: Capital Market, Friday, November 11th, 11:09 AM

Onco Therapies, a wholly owned subsidiary of Strides Arcolab has announced that it has received USFDA approval for Carboplatin Injection 10 mg/ ml packaged in 50 mg/ ml, 150 mg/15 ml, 450 mg/45 ml and 600 mg/ 60 ml Multi-dose vials.

According to IMS data June 2011, the US market for generic Carboplatin is approximately US$ 35 million. Carboplatin is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

The company made this announcement during the trading hours today, 11 November 2011.

TOP BLOGS

View all blogs